PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...

BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...

The FDA has granted fast track designation to DYNE-101, a therapy for myotonic dystrophy type 1 (DM1) now in testing in a ...

candidate for myotonic dystrophy type 1 (DM1), and del-brax for facioscapulohumeral muscular dystrophy (FSHD). All three candidates are based on the same TfR1-targeting antibody component.

facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1), as well as diseases affecting the heart. The company made its debut last year with a $51 million Series A and a licensing ...

The shares were sold at a weighted average price, with prices ranging from $28.59 to $28.63 per share, amounting to a total ...

This test is used to diagnose myotonic muscular dystrophy, which causes muscles to stay contracted for an abnormally long time. Facioscapulohumeral muscular dystrophy (FSH MD) begins in adolescence or ...

Max, Rowen, and Charlie are all living with Duchenne muscular dystrophy (DMD). These days, my gray hair and need for bifocals have me feeling like an older mom, but once upon a time, Jason and I were ...

After hours: January 27 at 6:48:09 p.m. EST Loading Chart for DYN ...